Akebia Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2836 www.akebia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics, Inc.

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - Jun 5th, 2025 2:33 pm
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Jun 4th, 2025 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2025 2:05 pm
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - May 28th, 2025 6:00 am
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - May 27th, 2025 6:00 am
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - May 13th, 2025 6:00 am
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - May 10th, 2025 6:35 am
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - May 9th, 2025 1:11 am
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - May 8th, 2025 6:15 am
Akebia Therapeutics: Q1 Earnings Snapshot - May 8th, 2025 5:18 am
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - May 8th, 2025 5:00 am
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - May 1st, 2025 8:01 am
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - May 1st, 2025 6:00 am
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Apr 10th, 2025 6:56 am
US High Growth Tech Stocks to Watch in 2023 - Apr 9th, 2025 5:38 am
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa - Apr 3rd, 2025 6:00 am
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - Mar 25th, 2025 6:00 am
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - Mar 21st, 2025 11:01 am
Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz - Mar 21st, 2025 10:16 am
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - Mar 21st, 2025 5:06 am